2 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMORecruiting
To study the feasiblity of cardiac MRI at 3T and the potential benefits of the intravascular contrast agent gadofosveset for studying and quantifiaction of heart function and -perfusion.